New patent on Hexvix granted in US
Oslo, Norway, 5 November 2007.
Photocure's strategy is to secure a broad and long lasting protection of its technology platform in key markets worldwide.
Photocure has received a notification from the United States Patent and Trademark Office stating that a patent application for Hexvix in the US has been granted. The new patent is valid until 2019 and extends the current patent protection for Hexvix in the US by 3 years.
President and CEO, Kjetil Hestdal says in a comment:
"We are very pleased to see this result of our continuous commitment to strengthen our intellectual property of existing and new products. This broadening and extension of current patent protection of Hexvix in US is a major contribution to secure the success of Hexvix."
For further information, please contact:
President and CEO Kjetil Hestdal
E-mail: kh@photocure.no
Mobile: +47 913 19 535
CFO Christian Fekete
E-mail: cf@photocure.no
Mobile: +47 916 42 938
www.photocure.com
Photocure ASA is a Norwegian pharmaceutical company listed on the Oslo Stock Exchange. The company develops and sells pharmaceuticals and medical devices for the photodynamic treatment and diagnosis of different types of cancer.
Photocure® has three products on the market: Metvix® cream combined with the Aktilite® lamp for the treatment of sun-damaged skin and certain types of skin cancer, and Hexvix® for the diagnosis of bladder cancer. In addition, the company has several follow-on products and technologies in the pipeline.